It’s worth noting that PD-1/PD-L1 immunotherapy antibodies are related to higher numbers of tumor-infiltrating T CD8+ cells, reinvigorate anti-tumor immunity, and improve patient outcomes [172,173]. Here, CD8A is linked to neoplasm.